DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Prolonged Hemodialysis Catheter Survival With Copolymer Coating and Rt-PA

Information source: Centre Hospitalier du Centre du Valais
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Malfunction; Catheter; Thrombosis; Mechanical Complication of Hemodialysis Catheter

Intervention: rt-PA (2mg/2mL) actilysis (Drug); rt-PA (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: Centre Hospitalier du Centre du Valais

Official(s) and/or principal investigator(s):
Pascal Meier, MD, Principal Investigator, Affiliation: CHCVs - RSV - Hôpital du Valais

Overall contact:
Pascal Meier, MD, Phone: +41276038647, Email: pascal.meier@hopitalvs.ch


Surface thrombogenicity of standard double lumen catheters (stDLC) and surface modified film-coated domain structured double lumen catheters (fcDLC) consisting of a novel reactive polyurethane copolymer coating showed that in vitro measured surface thrombogenicity was reduced in the modified catheter compared with standard catheter. The clinical investigation revealed that both number of days before catheter removal according to clinical requirements and number of treatments per catheter were significantly higher with the modified catheter as compared with the standard catheter. Recombinant tissue plasminogen activator (rt-PA) has been used primarily to treat catheter thrombosis. The relatively high cost of rt-PA and its theoretical potential to cause bleeding, as well as the morbidity and mortality associated with catheter malfunction and infection, justify the need for more definitive evidence of the efficacy of rt-PA as a locking solution. No study aims to evaluate the impact of rt-PA locking in long-term Hemodialysis (HD) uncuffed catheters survival.

Clinical Details

Official title: Prolonged Hemodialysis Catheter Survival With Copolymer Coating and Rt-PA - PROCOPrt-PA Trial

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Primary outcome: Lifespan patency with the ability to complete HD session in three different UCs using rt-PA locking protocol

Secondary outcome:

The incidence of catheter-related bacteremia after rt-PA use in case of thrombosed UCs

Economic evaluation of rt-PA in catheter patency after UCs dysfunction

Detailed description: The solution instilled into the central venous catheter lumens after each HD session and left in the catheter until the next session (catheter locking solution) is used to prevent thrombosis during the period between HD sessions and may also prevent catheter-related infection. However, evidence supporting the use of various locking solutions to achieve these objectives is limited. Heparin has been the traditional locking solution. Several small studies have assessed whether citrate and heparin are equally efficacious for maintaining catheter patency but the interpretation of the results was limited because the studies had a short follow-up period and included both uncuffed and cuffed central venous catheters. Thrombosis is a major cause of HD catheter dysfunction, and this problem is rectified by the use of thrombolytic agents, invasive procedures for declotting, or catheter replacement. A thrombus at the tip of the catheter or a fibrin sheath around it may resist local thrombolysis if it is not reached by sufficient concentrations of the drug. Urokinase has traditionally been used as the thrombolytic agent for HD vascular access declotting, and success rates for declotting vary from 55% to 85%. However, successful treatment of occluded central venous catheter (non HD) with recombinant tissue plasminogen activator (rt-PA) or alteplase was recently achieved in more than 1,000 patients with success (function restored in 798 patients [75. 0%; 95% CI: 72. 3 to 77. 6%]). Serious adverse events monitored within 30 days was very rare and efficacy was independent of age, sex, body weight, and catheter type.


Minimum age: 18 Years. Maximum age: 79 Years. Gender(s): Both.


Inclusion Criteria:

- End-stage kidney disease patients with newly inserted temporary untunnelled

dual-lumen catheter

- Naive to study but not naive to catheters (both virgin and non-virgin catheters will

be included)

- Expected to use catheter, and to dialyze at study centre, for at least six months

- Frequency of HD 3 times per week

- If indication for catheter was replacement for catheter related infection patients

will be eligible after the infection has been treated and the patient has been off antibiotics for 3 HD sessions

- Patient or legal representative able to provide written consent

- Eighteen years of age or older

- Baseline INR ≤ 1. 3 (no anticoagulation allowed outside the HD session)

- Baseline platelet count ≥ 60 x 109/L

Exclusion Criteria:

- Use of systemic anticoagulation (if indication for anticoagulation is catheter

patency patients may be eligible if the systemic anticoagulation is discontinued and baseline INR is ≤ 1. 3)

- Insertion of a new catheter into the femoral vein

- Current use of antibiotics for catheter-related bacteraemia (see inclusion criteria


- Major haemorrhage in the prior 4 weeks, defined as bleeding resulting in a drop in

haemoglobin of greater than 20 g/L or bleeding requiring transfusion of packed red blood cells with other clinical evidence or suspicion of bleeding

- History of intra-cranial bleed in the prior 4 weeks

- Intra-cranial or intra-spinal neoplasm (current)

- Allergy or intolerance to rt-PA or heparin or its constituents

- Active pericarditis - defined by the presence of a pericardial rub

- Weight ≤ 30 kg or > 130 kg

- Patient pregnant or lactating

- Child bearing potential (i. e. pre-menopausal woman who is not using a reliable method

of contraception)

- Major surgery in past 48 hours (CABG, organ biopsy, puncture of non-compressible

vessels), or scheduled for major surgery during the study period

- Involvement in another randomized drug trial

- Presence of a fever as defined by a temperature > 38. 2°C

Locations and Contacts

Pascal Meier, MD, Phone: +41276038647, Email: pascal.meier@hopitalvs.ch

Centre Hospitalier du Centre du Valais (CHCVs), Sion, Valais 1950, Switzerland; Recruiting
Pascal Meier, MD, Phone: +41276038647, Email: pascal.meier@hopitalvs.ch
Rachel Meier, SN, Sub-Investigator
Additional Information

Starting date: January 2011
Last updated: August 20, 2012

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017